NOVT: Recurring medical growth and proprietary platforms anchor a disciplined acquisition-led model
Novanta Inc. (NOVT) is projected to see its healthcare segment grow to approximately 60% of revenue by 2027, driven by consumables and advanced surgery. The company aims for mid- to high-single-digit organic growth and plans to deploy over $300 million in capital annually, according to insights from the Jefferies Global Healthcare Conference.
Aberdeen Group plc Purchases 3,883,199 Shares of Novanta Inc. $NOVT
Aberdeen Group plc acquired a significant new stake in Novanta Inc. during the third quarter, purchasing over 3.8 million shares valued at approximately $552 million, making it their 28th largest position. Despite mixed analyst ratings, with a consensus "Hold" and a $175 price target, Novanta surpassed its Q3 earnings and revenue estimates. The technology company reported an EPS of $1.05 against an expected $0.97 and revenue of $305 million, a 23.1% increase year-over-year.
What Novanta (NOVT) Said on Its Q3 Earnings Call
Novanta (NOVT) reported strong Q3 financial results, with revenue up 23% and significant organic growth driven by demand in robotics and advanced manufacturing. The company also completed its largest acquisition, Riverpoint Medical, which boosted its medical consumables business. Despite a temporary delay in lithography product shipments and a dip in precision medicine sales, Novanta provided a positive outlook, forecasting continued revenue and adjusted EBITDA growth for the fourth quarter and 2027.
Earnings call transcript: Novanta tops Q3 2026 estimates but shares slip
Novanta (NOVT) exceeded Wall Street's Q3 2026 expectations with adjusted earnings of $1.05 per share on $305 million in revenue, driven by 23% revenue growth and 10% organic growth. Despite these strong results, including record adjusted EBITDA margins and robust bookings, shares slipped in premarket trading due to a temporary production setback in the U.K. and a cautious near-term outlook. The company remains optimistic about 2027, anticipating over 15% reported growth and more than 20% adjusted EBITDA growth as manufacturing challenges are resolved.
Novanta Announces Financial Results for the Third Quarter 2026
Novanta reported a 23% increase in third-quarter 2026 GAAP revenue to $305 million, partly due to its largest acquisition, Riverpoint Medical. While GAAP net income decreased, adjusted EBITDA rose by 38%, and the company raised its full-year 2026 guidance, reflecting positive impacts from the acquisition. However, GAAP profit margins remained thin, and GAAP operating income declined.
Novanta (NOVT) to report earnings tomorrow: here is what to expect
Novanta (NOVT), a medicine and manufacturing technology provider, is set to report its Q3 earnings, with analysts expecting a 21.5% year-on-year revenue growth. The company previously exceeded revenue expectations last quarter, and its EBITDA and revenue guidance also surpassed analyst forecasts. While Novanta has missed revenue estimates multiple times in the past two years, analysts have generally maintained their estimates for the upcoming report.
Liquidity Mapping Around (NOVT) Price Events
Stock Traders Daily provides a liquidity mapping analysis for Novanta Inc. (NASDAQ: NOVT), indicating strong sentiment across all horizons and an overweight bias. The analysis highlights an exceptional short setup targeting 12.5% downside and offers three distinct AI-generated trading strategies: Position, Momentum Breakout, and Risk Hedging, along with multi-timeframe signal analysis.
Novanta Inc. (NOVT) Stock Forecasts
Novanta Inc. (NOVT) is a manufacturer of photonic and motion-control components for OEMs in the medical and industrial technology sectors. Argus recently raised its target price for NOVT to $157.00, with the stock currently trading at $149.32.
Sterling Capital Management LLC Sells 9,110 Shares of Novanta Inc. $NOVT
Sterling Capital Management LLC significantly reduced its stake in Novanta Inc. by 88.4% in the third quarter, selling 9,110 shares and retaining 1,197 shares. Despite this, other institutional investors largely increased their positions, maintaining high institutional ownership at 98.35%. Novanta exceeded quarterly earnings and revenue estimates, and analysts currently hold a consensus "Hold" rating with a target price of $194.00, while the stock recently traded at $145.76.
NOVT: Novanta Inc Latest Stock Price, Analysis, News and Trading Ideas
This article provides an overview of Novanta Inc. (NOVT), including its latest stock price, market capitalization, and key financial metrics. It details the company's business segments, Automation Enabling Technologies and Medical Solutions, and highlights recent news such as Q3 earnings beats for related companies and Novanta's upcoming presentation at a conference. The article also includes a section on investor sentiment and trending discussions.
Novanta (NASDAQ:NOVT) Shares Cross Above 200 Day Moving Average - Should You Sell?
Novanta Inc. (NASDAQ:NOVT) shares recently rose 2.3% to $144.02, crossing above their 200-day moving average of $141.92, with a high of $146.33. Despite a consensus "Hold" rating from analysts, the company exceeded quarterly expectations with $0.89 EPS on $265.81 million in revenue. Institutional investors hold a significant 98.35% of the shares.
Novanta Inc. Estimates – NASDAQ:NOVT
This article provides an overview of Novanta Inc.'s financial data and analyst estimates on TradingView. It allows users to explore reported financial data and compare actual results with average, high, and low estimates across income statements, balance sheets, cash flow statements, and valuation metrics. The platform also visualizes trends over time for both annual and quarterly data.
Novanta to Present at the Baird 2026 Global Industrial Conference on Wednesday, November 11, 2026
Novanta Inc. announced that its Chief Financial Officer, Robert Buckley, and Chief Operating Officer of Medical Solutions, John Lesica, are scheduled to present at the Baird 2026 Global Industrial Conference on November 11, 2026, in Chicago, Illinois. Novanta is a global supplier of core technology solutions for medical, life science, and advanced industrial equipment manufacturers. The company's common shares are traded on Nasdaq under the ticker symbol "NOVT."
Novanta to Present at the Baird 2026 Global Industrial Conference on Wednesday, November 11, 2026
Novanta Inc. announced that its Chief Financial Officer, Robert Buckley, and Chief Operating Officer of Medical Solutions, John Lesica, are scheduled to present at the Baird 2026 Global Industrial Conference on Wednesday, November 11, 2026, in Chicago, Illinois. The company is a technology partner to medical and advanced technology equipment manufacturers, providing core technology solutions. Novanta's common shares are traded on Nasdaq under the ticker symbol "NOVT."
Novanta Inc. Announces Schedule of Third Quarter 2026 Earnings Release and Conference Call
Novanta Inc. (Nasdaq: NOVT) will release its third quarter 2026 financial results on Monday, November 9, 2026, after U.S. financial markets close. The company will host a conference call on Tuesday, November 10, 2026, at 8:00 a.m. ET to discuss these results, with access available by phone or live webcast. An audio webcast replay will be available on Novanta's investor relations website until December 28, 2026.
Argus raises Novanta stock target to USD 157.00
Argus has raised its price target for Novanta (NOVT) to USD 157.00, representing a 15.97% increase above the current Nasdaq price. This adjustment comes as Novanta prepares to release its third-quarter results on November 9, 2026. The stock's current market capitalization is USD 5.1 billion with a P/E ratio of 86.56, and it trades significantly below its 52-week high.
Novanta Inc. Announces Schedule of Third Quarter 2026 Earnings Release and Conference Call
Novanta Inc. (Nasdaq: NOVT) will release its third quarter 2026 financial results after the U.S. financial markets close on Monday, November 9, 2026. The company will host a conference call the following day, Tuesday, November 10, 2026, at 8:00 a.m. ET to discuss the results. Interested parties can access the call via phone or a live webcast on Novanta's investor relations website.
Novanta Inc. Announces Schedule of Third Quarter 2026 Earnings Release and Conference Call
Novanta Inc. (Nasdaq: NOVT) has announced it will release its third quarter 2026 financial results after the close of U.S. financial markets on Monday, November 9, 2026. The company will host a conference call the following day, November 10, 2026, at 8:00 a.m. ET to discuss these results, with access available via dial-in or live webcast. A replay of the webcast will also be available on their investor relations page until December 28, 2026.
Novanta Inc. Announces Schedule of Third Quarter 2026 Earnings Release and Conference Call
Novanta Inc. (Nasdaq: NOVT) will release its third quarter 2026 financial results after the U.S. financial markets close on Monday, November 9, 2026. The company will host a conference call on Tuesday, November 10, 2026, at 8:00 a.m. ET to discuss these results. A live webcast and replay will be available on the Investors section of Novanta's website.
Novanta (NOVT) Stock Looks Priced For Perfection After A 41% Run
Novanta (NOVT) stock has seen a 41.3% return over the past year, leading to a high P/E ratio of 86.5x, significantly above its industry average. This valuation suggests the market has high confidence in its future earnings and profit durability, raising questions about whether the current price is justified by its underlying earnings power. Investors are encouraged to consider the company's P/E in relation to its sector and a tailored benchmark to assess if the premium is warranted.
Here's How Much $100 Invested In Novanta 15 Years Ago Would Be Worth Today
Novanta (NASDAQ: NOVT) has shown significant outperformance over the last 15 years, with an average annual return of 20.4%, exceeding the market by 7.15% on an annualized basis. An initial investment of $100 in Novanta 15 years ago would now be worth $1,552.20, highlighting the power of compounded returns. The company currently holds a market capitalization of $4.86 billion.
FuelCell Energy, Novanta, FTAI Infrastructure, NN, and Hertz Shares Are Falling, What You Need To Know
Shares of FuelCell Energy, Novanta, FTAI Infrastructure, NN, and Hertz fell following reports of explosions in Saudi Arabia and escalating clashes near maritime shipping straits, causing crude oil prices to surge over 5%. This geopolitical instability, coupled with high U.S. Treasury yields, rattled investor confidence and raised concerns about global energy supply and persistent inflation. The market's reaction to these events led to a "risk-off" positioning across major equity indices, impacting various companies including those in renewable energy, electronic components, and ground transportation.
S&P 500 Futures Drop in Premarket Trading; Bending Spoons, Novanta Lag
S&P 500 futures dropped in premarket trading. Equifax Inc. (EFX) and Archrock Inc. (AROC) were among the stocks showing gains before the market opened.
Novanta (NASDAQ:NOVT) Stock Rating Lowered by Zacks Research
Zacks Research downgraded Novanta (NASDAQ:NOVT) from a "strong-buy" to a "hold" rating, aligning with the overall analyst consensus of "Hold" and a $194 price target. Despite the downgrade, Novanta exceeded quarterly expectations with adjusted EPS of $0.89 and revenue of $265.81 million, marking a 10.3% year-over-year increase. The stock opened down 3.7% at $143.64, with institutional investors holding a significant 98.35% of its shares.
Novanta Inc. (NOVT) Stock Forecasts
Argus has lowered its target price for Novanta Inc. (NOVT) to $148.00. Novanta Inc. manufactures photonic and motion-control components for original equipment manufacturers in the medical equipment and industrial technology markets. The current stock price for NOVT is $149.10.
FuelCell Energy, Nextpower, Wabash, Avis Budget Group, and Novanta Shares Skyrocket, What You Need To Know
Shares of FuelCell Energy, Nextpower, Wabash, Avis Budget Group, and Novanta surged in the morning session after weaker-than-expected US employment data led to a cool-down in Treasury yields. The Bureau of Labor Statistics reported that nonfarm payrolls rose by only 29,000 in September, significantly below the projected 84,000, causing a slump in Treasury yields as expectations for a Federal Reserve rate hike diminished. FuelCell Energy, specifically, saw a 6.8% jump and is up 118% year-to-date, partially due to an "Outperform" rating from Oppenheimer.
Novanta (NASDAQ:NOVT) Stock Breaks Below Fifty Day Moving Average - Time to Sell?
Novanta (NASDAQ:NOVT) stock recently fell below its 50-day moving average, trading at $143.58 against an average of $147.16. Despite this technical dip, analysts maintain a "Buy" rating with an average target price of $194, supported by the company exceeding recent quarterly earnings and revenue expectations. Institutional investors hold a significant portion of the stock, with many increasing their positions, indicating continued confidence.
A Look at Novanta Inc (NOVT) After 7.3% Gain -- GF Value $156.35 vs Price $144.17
Novanta Inc (NOVT) saw its shares rise 7.3% to $144.17, placing it 7.8% below its estimated GF Value™ of $156.35, suggesting it is undervalued. The company holds a strong GF Score™ of 88/100, driven by high valuation and momentum scores, despite a lower growth rating. While gurus are generally positive, insider selling without buying activity raises a cautionary flag for investors.
Novanta Jumps 5.1% Amid Sector-Wide Rally
Novanta Inc. (NOVT) surged 5.1% to close at $141.16 on Tuesday, driven by a broad sector-wide rally among scientific and technical instruments makers. This movement is attributed to coordinated buying across the sector, rather than company-specific news, suggesting investor confidence in the industrial technology market. The gains reflect broader market sentiment and potential repositioning by institutional investors, with strong demand trends in markets like medical devices and robotics.
Is Novanta (NOVT) A Bargain Following Strong Growth And Demand Outlook?
This article analyzes Novanta (NOVT) stock, highlighting a split sentiment among investors. While many believe the stock is undervalued with a fair value of $194.50 due to its growth profile and strategic acquisitions, others view it as expensive given its high P/E ratio of 81.5x compared to industry averages. The piece encourages further analysis to weigh the potential rewards and warning signs before making investment decisions.
California State Teachers Retirement System Increases Stock Position in Novanta Inc. $NOVT
The California State Teachers Retirement System increased its stake in Novanta Inc. by 0.3% in the second quarter, now owning 41,758 shares valued at approximately $6.77 million. Other institutional investors like Bamco Inc. NY and William Blair Investment Management LLC also made significant investments. Novanta reported strong Q2 earnings, beating analyst estimates for both EPS and revenue, and has a "Buy" consensus rating from analysts with a target price of $194.00.
Novanta director Thomas Secor sells $97,858 in stock
Novanta director Thomas N. Secor sold 663 shares of the company's common stock for a total of $97,858 on September 11, 2026, as part of a pre-established trading plan. Despite the stock declining approximately 6% over the past week and appearing overvalued according to InvestingPro analysis, Novanta recently surpassed Q2 2026 earnings and revenue expectations, leading to an increased financial outlook. Secor now directly holds 662 shares of Novanta.
Novanta (NASDAQ: NOVT) director lines up $97.9K stock sale
Novanta director Thomas N. Secor has filed a Rule 144 notice to sell 663 shares of NOVANTA INC common stock, which were acquired through restricted stock vesting on January 2, 2026. The proposed sale, valued at approximately $97,858.80, will be executed through Fidelity Brokerage Services LLC on Nasdaq. This filing provides transparency into insider stock transactions and the process for selling restricted shares.
Tidal Investments LLC Has $5.62 Million Stock Position in Novanta Inc. $NOVT
Tidal Investments LLC significantly increased its stake in Novanta Inc. (NASDAQ:NOVT) by 615.8% in the second quarter, now holding 34,631 shares valued at $5.62 million. Other institutional investors have also adjusted their positions, with institutional ownership of the company at 98.35%. Novanta recently reported strong quarterly earnings, exceeding analyst expectations, and maintains a positive outlook from analysts with an average "Buy" rating and a $194 price target.
Novanta director Thomas Secor sells $97,858 in stock By Investing.com
Novanta Inc. director Thomas N. Secor sold 663 shares of company stock for a total of $97,858 on September 11, 2026, under a pre-established trading plan. Following this transaction, Mr. Secor directly holds 662 shares. The stock has seen a recent decline, and an InvestingPro analysis suggests it may be overvalued, despite the company recently exceeding Q2 2026 earnings and revenue expectations and raising its financial outlook.
Novanta to Present at Baird Global Healthcare Conference on Tuesday, September 15, 2026
Novanta Inc. announced that its Chief Financial Officer, Robert Buckley, and Chief Operating Officer of Medical Solutions, John Lesica, will present at the Baird Global Healthcare Conference on Tuesday, September 15, 2026, in New York, NY. The company, traded on Nasdaq under "NOVT," is a leading global supplier of core technology solutions for medical and advanced industrial original equipment manufacturers. They specialize in precision medicine and manufacturing, medical solutions, and robotics and automation.
Novanta to Present at Baird Global Healthcare Conference on Tuesday, September 15, 2026
Novanta Inc. announced that its CFO, Robert Buckley, and COO of Medical Solutions, John Lesica, are scheduled to present at the Baird Global Healthcare Conference on September 15, 2026, in New York, NY. The company, a leading supplier of core technology solutions for medical and advanced industrial manufacturers, combines proprietary technology with expertise in precision medicine, manufacturing, and robotics. Novanta's common shares are traded on Nasdaq under the ticker symbol "NOVT".
Novanta Inc (NOVT) Shares Fall 3.9% -- What GF Score of 88 Tells Investors
Novanta Inc (NOVT) shares dropped 3.9% to $139.48, yet are considered "Modestly Undervalued" by GuruFocus's GF Value with a strong GF Score of 88/100. While the company exhibits high financial strength and profitability, insider selling without buying activity raises caution, despite positive sentiment from five gurus. Investors are advised to monitor performance and consider both the undervaluation and potential risks.
Here’s How Much You Would Have Made Owning Novanta Stock In The Last 10 Years
Novanta (NASDAQ: NOVT) has significantly outperformed the market over the last decade, with an annualized return of 23.93%. An investment of $100 in Novanta stock 10 years ago would now be worth $862.47, demonstrating the powerful effect of compounded returns. The company currently holds a market capitalization of $5.17 billion.
Here’s How Much You Would Have Made Owning Novanta Stock In The Last 10 Years
Novanta (NASDAQ: NOVT) has significantly outperformed the market over the last decade, with an annualized return of 23.93%. An initial investment of $100 in NOVT stock ten years ago would now be worth $862.47, highlighting the power of compounded returns.
39,140 Shares in Novanta Inc. $NOVT Acquired by Summit Creek Advisors LLC
Summit Creek Advisors LLC has acquired 39,140 shares of Novanta Inc. (NASDAQ:NOVT) worth approximately $6.35 million, making it their 19th largest position. Other institutional investors have also adjusted their stakes in Novanta, while CEO Matthijs Glastra recently sold 6,500 shares. Novanta reported strong quarterly earnings, beating estimates, and analysts maintain a "Buy" consensus rating with an average target price of $194.00.
17,392 Shares in Novanta Inc. $NOVT Bought by Diversify Advisory Services LLC
Diversify Advisory Services LLC has acquired a new stake of 17,392 shares in Novanta Inc. (NASDAQ:NOVT) during the second quarter, valued at approximately $2.45 million. Other institutional investors also increased their holdings in Novanta, which saw its stock trading down 6.9% at $157.11. The company reported strong Q2 earnings, beating analyst estimates, and has received updated "Strong Buy" and "Buy" ratings from several analysts, with an average target price of $194.00.
A Look at Novanta Inc (NOVT) After 6.9% Decline -- GF Value $154
Novanta Inc (NOVT) shares recently declined by 6.9% to $157.14, yet the stock remains 2.0% overvalued according to its GF Value™ of $154.02. Despite a strong GF Score™ of 87/100, indicating robust overall performance, the company's P/E ratio is higher than its historical median, and insiders have sold $11.5 million in shares over the past year with no buying activity. Investors are advised to consider these factors, including potential risks associated with its overvaluation and insider selling, before making investment decisions.
Federated Hermes SDG Engagement Equity Fund's Novanta Inc(NOVT) Holding History
Federated Hermes SDG Engagement Equity Fund holds 10,027.00 shares of Novanta Inc (NOVT), valued at $1.30 million, making up 1.49% of their portfolio. The initial purchase was in Q2 2026 at an average price of $129.49 per share. As of the current price of $166.57, the fund has an estimated gain of $371,801.16, representing a 28.64% return on this holding.
Oppenheimer Asset Management Inc. Buys New Stake in Novanta Inc. $NOVT
Oppenheimer Asset Management Inc. has acquired a new stake in Novanta Inc. (NASDAQ:NOVT), purchasing 35,729 shares valued at approximately $5.8 million, making institutional investors collectively own 98.35% of the company. Novanta recently exceeded quarterly earnings expectations with $0.89 EPS and $265.8 million in revenue, and has provided positive fiscal 2026 EPS guidance. Despite a CEO insider sale, analysts maintain a consensus "Hold" rating with a price target of $194.
T. Rowe Price (NOVT) discloses 6.2% beneficial stake in Novanta common stock
T. Rowe Price Associates, Inc. has disclosed a 6.2% beneficial ownership stake in Novanta Inc. (NOVN), amounting to 2,222,444 shares of common stock. The firm reported sole voting power over 2,216,715 shares and sole dispositive power over all 2,222,444 shares, while explicitly denying that the report constitutes an admission of beneficial ownership. This disclosure was made via a Schedule 13G SEC filing.
Are You Looking for a Top Momentum Pick? Why Novanta (NOVT) is a Great Choice
Novanta (NOVT) is highlighted as a strong momentum pick due to its Zacks Momentum Style Score of B and Zacks Rank of #2 (Buy). The article details NOVT's impressive short-term and long-term price performance, outperforming both its industry and the S&P 500. Additionally, positive earnings estimate revisions further support its promising outlook for investors.
Wasatch Advisors LP Has $123.30 Million Stock Position in Novanta Inc. $NOVT
Wasatch Advisors LP reduced its holdings in Novanta Inc. by 23.7% in the second quarter, now owning 759,992 shares valued at $123.3 million. Despite this, institutional investors collectively hold 98.35% of Novanta's stock. The company recently exceeded earnings estimates, reporting $0.89 per share on revenue of $265.81 million, though analyst sentiment remains cautious with a "Hold" consensus rating and a $194.00 price target.
Novanta Inc. $NOVT Shares Bought by Bank of America Corp DE
Bank of America Corp DE significantly increased its stake in Novanta Inc. (NASDAQ:NOVT) by 18.3% in the first quarter, now owning 456,241 shares valued at $53.9 million. Novanta exceeded quarterly earnings expectations with $0.89 EPS and $265.81 million in revenue, and analysts currently hold a consensus "Hold" rating with a $194 price target. CEO Matthijs Glastra also sold 6,500 shares under a pre-arranged trading plan.
Avoiding Lag: Real-Time Signals in (NOVT) Movement
This article analyzes Novanta Inc. (NASDAQ: NOVT) using AI-generated real-time signals, indicating a strong overweight bias across all time horizons. It highlights an exceptional risk-reward short setup and provides specific trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—with entry zones, targets, and stop losses. The analysis also includes multi-timeframe signal strengths and support/resistance levels to help traders navigate NOVT's movement.